Rare disease news, mapped to the diseases behind the headlines. AI-classified across pipeline, policy, funding, science, and community.
Be among the first to receive Kisho Intelligence Briefings
Showing news related to
Showing 1–3 of 3 stories
BioCryst is acquiring Astria Therapeutics in a cash-and-stock deal to enhance its portfolio with a long-acting preventive therapy for hereditary angioedema. This acquisition reflects a strategic shift in venture firms' preferences as the biotech sector recovers.
Read full storyA study published in PubMed highlights the patient experience of hereditary angioedema, focusing on a racially diverse sample of adult patients. The findings aim to enhance understanding of the condition's impact on different demographics.
Intellia is set to report Phase 3 trial results for a potential treatment for hereditary angioedema in the first half of 2026, amidst a backdrop of significant clinical trial activity in rare diseases. Despite recent challenges, including a study participant's death and program suspensions, the biotech sector is regaining momentum with key readouts expected across various conditions.
Get the week's most important rare disease developments — pipeline moves, policy changes, and funding signals — delivered to your inbox every Monday.
Free weekly briefing. Unsubscribe anytime.